Does the media refer more to COYA or KMDA?

In the previous week, Coya Therapeutics had 1 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for Kamada. Coya Therapeutics' average media sentiment score of 0.56 beat Kamada's score of 0.40 indicating that Coya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kamada 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TECX or COYA?

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.95 beat Coya Therapeutics' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or COYA?

In the previous week, Editas Medicine had 12 more articles in the media than Coya Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 3 mentions for Coya Therapeutics. Editas Medicine's average media sentiment score of 0.64 beat Coya Therapeutics' score of 0.56 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CAPR or COYA?

In the previous week, Capricor Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 6 mentions for Capricor Therapeutics and 3 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.56 beat Capricor Therapeutics' score of 0.47 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COYA or DMAC?

In the previous week, Coya Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Coya Therapeutics' score of 0.56 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DiaMedica Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Coya Therapeutics (COYA) Competitors

$4.18 -0.29 (-6.49%)

Closing price 04:00 PM Eastern

Extended Trading

$4.22 +0.04 (+0.93%)

As of 06:39 PM Eastern

Compare

COYA vs. KMDA, TECX, EDIT, CAPR, and DMAC

Should you buy Coya Therapeutics stock or one of its competitors? Coya Therapeutics's main competitors and comparable companies include Kamada (KMDA), Tectonic Therapeutic (TECX), Editas Medicine (EDIT), Capricor Therapeutics (CAPR), and DiaMedica Therapeutics (DMAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coya Therapeutics compare to Kamada?

Coya Therapeutics (NASDAQ:COYA) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Kamada has a net margin of 11.60% compared to Coya Therapeutics' net margin of -270.22%. Kamada's return on equity of 8.37% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Kamada	11.60%	8.37%	5.85%

Coya Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Kamada has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market.

Coya Therapeutics presently has a consensus price target of $15.33, suggesting a potential upside of 243.03%. Kamada has a consensus price target of $13.50, suggesting a potential upside of 75.55%. Given Coya Therapeutics' higher probable upside, research analysts clearly believe Coya Therapeutics is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Kamada	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.19	-$21.23M	-$1.07	N/A
Kamada	$180.46M	2.45	$20.20M	$0.38	20.24

In the previous week, Coya Therapeutics had 1 more articles in the media than Kamada. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for Kamada. Coya Therapeutics' average media sentiment score of 0.56 beat Kamada's score of 0.40 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kamada	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Kamada beats Coya Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Coya Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Tectonic Therapeutic presently has a consensus target price of $69.17, indicating a potential upside of 224.57%. Coya Therapeutics has a consensus target price of $15.33, indicating a potential upside of 243.03%. Given Coya Therapeutics' higher possible upside, analysts clearly believe Coya Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.80
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Coya Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Coya Therapeutics	$7.95M	13.19	-$21.23M	-$1.07	N/A

Tectonic Therapeutic has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Tectonic Therapeutic's return on equity of -35.26% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Tectonic Therapeutic and Tectonic Therapeutic both had 3 articles in the media. Tectonic Therapeutic's average media sentiment score of 0.95 beat Coya Therapeutics' score of 0.56 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Summary

Tectonic Therapeutic beats Coya Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, media sentiment, valuation and institutional ownership.

Editas Medicine has a net margin of -157.32% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-157.32%	-196.63%	-38.17%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Editas Medicine has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Editas Medicine had 12 more articles in the media than Coya Therapeutics. MarketBeat recorded 15 mentions for Editas Medicine and 3 mentions for Coya Therapeutics. Editas Medicine's average media sentiment score of 0.64 beat Coya Therapeutics' score of 0.56 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	5 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Coya Therapeutics has lower revenue, but higher earnings than Editas Medicine. Coya Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	9.25	-$160.06M	-$0.75	N/A
Coya Therapeutics	$7.95M	13.19	-$21.23M	-$1.07	N/A

Editas Medicine presently has a consensus target price of $5.83, suggesting a potential upside of 139.07%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 243.03%. Given Coya Therapeutics' higher probable upside, analysts plainly believe Coya Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Editas Medicine beats Coya Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Coya Therapeutics compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Coya Therapeutics (NASDAQ:COYA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Capricor Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Coya Therapeutics	-270.22%	-52.05%	-46.34%

Capricor Therapeutics currently has a consensus price target of $30.25, suggesting a potential upside of 339.68%. Coya Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 243.03%. Given Capricor Therapeutics' higher possible upside, research analysts clearly believe Capricor Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Capricor Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Coya Therapeutics has lower revenue, but higher earnings than Capricor Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	17.96	-$105.04M	-$2.45	N/A
Coya Therapeutics	$7.95M	13.19	-$21.23M	-$1.07	N/A

In the previous week, Capricor Therapeutics had 3 more articles in the media than Coya Therapeutics. MarketBeat recorded 6 mentions for Capricor Therapeutics and 3 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.56 beat Capricor Therapeutics' score of 0.47 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Capricor Therapeutics beats Coya Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Coya Therapeutics compare to DiaMedica Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Coya Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 243.03%. DiaMedica Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 53.45%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Coya Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

DiaMedica Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Coya Therapeutics' return on equity of -52.05% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
DiaMedica Therapeutics	N/A	-77.76%	-69.43%

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 5.0% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Coya Therapeutics has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.19	-$21.23M	-$1.07	N/A
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A

Coya Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, DiaMedica Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

In the previous week, Coya Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Coya Therapeutics and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.49 beat Coya Therapeutics' score of 0.56 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DiaMedica Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Coya Therapeutics beats DiaMedica Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Coya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COYA vs. The Competition

Export

Metric	Coya Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$98.06M	$3.90B	$7.28B	$12.93B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-3.91	12.62	275.31	25.30
Price / Sales	12.33	1,151.52	556.94	76.39
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	2.03	16.54	10.51	5.92
Net Income	-$21.23M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-14.87%	-6.64%	-4.33%	-4.39%
1 Month Performance	-9.91%	-14.39%	-8.64%	-7.26%
1 Year Performance	-41.94%	6.01%	2.04%	-4.95%

Coya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COYA Coya Therapeutics	2.3067 of 5 stars	$4.18 -6.5%	$15.33 +266.8%	-26.2%	$98.06M	$7.95M	N/A	8	News Coverage Gap Up
KMDA Kamada	4.872 of 5 stars	$8.07 +3.7%	$13.50 +67.3%	+11.8%	$464.11M	$180.46M	21.24	462
TECX Tectonic Therapeutic	2.879 of 5 stars	$23.39 +2.8%	$77.80 +232.7%	+32.4%	$457.55M	N/A	N/A	60	Analyst Upgrade
EDIT Editas Medicine	2.3936 of 5 stars	$2.96 +4.0%	$5.83 +97.4%	-31.5%	$453.83M	$47.01M	N/A	87
CAPR Capricor Therapeutics	2.748 of 5 stars	$7.84 -2.2%	$30.25 +286.1%	+2.4%	$452.62M	$22.27M	N/A	231

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COYA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coya Therapeutics (COYA) Competitors

COYA vs. KMDA, TECX, EDIT, CAPR, and DMAC

How does Coya Therapeutics compare to Kamada?

Summary

How does Coya Therapeutics compare to Tectonic Therapeutic?

Summary

How does Coya Therapeutics compare to Editas Medicine?

Summary

How does Coya Therapeutics compare to Capricor Therapeutics?

Summary

How does Coya Therapeutics compare to DiaMedica Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coya Therapeutics (COYA) Competitors

COYA vs. KMDA, TECX, EDIT, CAPR, and DMAC

How does Coya Therapeutics compare to Kamada?

Is COYA or KMDA more profitable?

Which has more volatility and risk, COYA or KMDA?

Do analysts prefer COYA or KMDA?

Which has higher earnings & valuation, COYA or KMDA?

Does the media refer more to COYA or KMDA?

Do institutionals and insiders have more ownership in COYA or KMDA?

Summary

How does Coya Therapeutics compare to Tectonic Therapeutic?

Do analysts prefer TECX or COYA?

Which has better earnings & valuation, TECX or COYA?

Is TECX or COYA more profitable?

Do institutionals & insiders have more ownership in TECX or COYA?

Does the media favor TECX or COYA?

Which has more risk & volatility, TECX or COYA?

Summary

How does Coya Therapeutics compare to Editas Medicine?

Is EDIT or COYA more profitable?

Which has more risk & volatility, EDIT or COYA?

Do institutionals and insiders hold more shares of EDIT or COYA?

Does the media favor EDIT or COYA?

Which has higher earnings and valuation, EDIT or COYA?

Do analysts recommend EDIT or COYA?

Summary

How does Coya Therapeutics compare to Capricor Therapeutics?

Do institutionals & insiders hold more shares of CAPR or COYA?

Is CAPR or COYA more profitable?

Do analysts recommend CAPR or COYA?

Which has more risk and volatility, CAPR or COYA?

Which has preferable valuation and earnings, CAPR or COYA?

Does the media favor CAPR or COYA?

Summary

How does Coya Therapeutics compare to DiaMedica Therapeutics?

Do analysts rate COYA or DMAC?

Is COYA or DMAC more profitable?

Do insiders & institutionals hold more shares of COYA or DMAC?

Which has better earnings and valuation, COYA or DMAC?

Which has more volatility & risk, COYA or DMAC?

Does the media refer more to COYA or DMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COYA vs. The Competition

Coya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools